ABL Bio
Company Details
Status: Public
Employees: 51-100
Location:
Seongnam-si, Gyeonggi-do, South Korea
Type:
sample
Technology:
sample
sample
sample
sample
About: ABL Bio Inc. (Kosdaq: 298380) is a South Korean biotechnology company dedicated to the development of bispecific antibody therapeutics to improve and save people's lives.
With our BsAb platforms ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B,’ we have built a robust pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated excellent efficacy and safety. We also created a next-generation antibody drug conjugate program to treat various cancers.
In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration.
We continue to actively expand and advance our pipeline through global strategic partnerships. For more information, please visit http://ablbio.com
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
ABL Bio | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.